Strategic Acquisition Opportunity: Biotechnology Intellectual Property of Civetta Therapeutics, LLC Now Open for Bids
04 Apr 2024
AcquisitionPROTACs
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- The Assignee of Civetta Therapeutics, LLC, a trailblazer in the field of biotechnology with a focus on β-propeller protein research, is inviting bids for the company's rich portfolio of intellectual property. Following the cessation of operations on December 22, 2023, and its transition into an Assignment for the Benefit of Creditors, the Assignee is seeking competitive offers for Civetta's extensive collection of innovative research and assets in biotechnology.
Civetta Therapeutics has been at the forefront of biotechnological innovation, specializing in the exploration of β-propeller proteins, which present over 600 target opportunities for various diseases. The company's groundbreaking approach has opened new paths in addressing challenges in oncology, neurodegeneration, inflammation, and monogenic diseases. With a skilled team based in Cambridge, MA, and advanced research facilities, Civetta has developed a novel class of therapies and a robust platform for drug discovery in this promising area of biotechnology.
Investment Opportunity:
The available intellectual property portfolio offers a unique opportunity to invest in a cutting-edge area of biotechnology. Highlights of the portfolio include a late-stage chemically enabled oncology program, validated small molecule hits for another oncology initiative, and comprehensive tools and methodologies for advancing B-propeller protein research and drug discovery.
This is a rare opportunity to acquire a comprehensive portfolio of intellectual property in a field with immense therapeutic and commercial potential. Interested parties are encouraged to act promptly to participate in this unique acquisition process.
Bid Submission Details:
Interested parties are invited to submit their bids for Civetta Therapeutics' intellectual property by April 30, 2024, 5:00 PM Central Time. A confidentiality and non-disclosure agreement will grant qualified bidders access to a virtual data room for due diligence. The bid process is structured to ensure fairness and transparency, with detailed submission guidelines available upon request.
All inquiries should be directed to representatives of the Assignee, Development Specialists, Inc. For inquiries and further information regarding the bid submission process, please contact William G. Brandt at (312) 263-4141 or wgbrandt@dsiconsulting.com or Matthew Sorenson at msorenson@dsiconsulting.com
About DSI
Development Specialists, Inc. (DSI) is one of the leading providers of management consulting and financial advisory services, including turnaround consulting, financial restructuring, litigation support, fiduciary services and forensic accounting. Our clients include business owners, private-equity investors, corporate boards, financial institutions, secured lenders, bondholders and unsecured creditors.
View source version on businesswire.com:
Contacts
Media Contact: Mark Fleming mfleming@dsiconsulting.com
Source: Development Specialists, Inc.
View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.